CorMedix Inc. announced the appointment of Thomas Nusbickel to the newly created position of Chief Commercial Officer. Tom will be responsible for advancing the commercial strategy needed to bring DefenCath to patients in the US when approved by FDA for commercial distribution. Tom most recently served as Vice President of Market Access and Government Affairs at Coherus Biosciences. Previously, Tom served as Chief Commercial Officer at Opko Inc.